{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:57:40Z","timestamp":1790675860641,"version":"4.1.0"},"reference-count":173,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Kidney transplantation (KT) remains the optimal therapy for end-stage kidney disease (ESKD), yet long-term graft survival is limited by unremitting allograft dysfunction and non-immune treatment toxicities. Sterile inflammation primarily drives graft failure. This inflammatory process releases damage-associated molecular patterns (DAMPs). DAMPs activate pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) 2 and 4, from proximal tubule epithelial cells, endothelial compartments, and infiltrating myeloid lineages. PRR signaling and the release of pro-inflammatory cytokines (IL-1\u03b2, IL-18, TNF-\u03b1) promote pro-inflammatory M1 macrophage polarization and accelerate interstitial fibrosis and tubular atrophy (IFTA). While maintenance immunosuppression prevents adaptive rejection, it causes severe metabolic, cardiovascular, and oncologic complications, including post-transplant diabetes mellitus, hypertension, and malignancies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin, empagliflozin, canagliflozin) have emerged as novel disease-modifying, immunomodulatory adjuncts that act independently of glycemic control. SGLT2 inhibition reactivates tubuloglomerular feedback to relieve intraglomerular hypertension, blunts hyperfiltration, and reduces tubular transport workload. This alleviates cortical hypoxia, curtails mitochondrial ROS production, and activates AMP-activated protein kinase (AMPK) to suppress NF-\u03baB and NLRP3 inflammasome assembly. SGLT2 inhibitors downregulate TLR expression, drive a phenotypic shift toward reparative M2 macrophages, reduce proteinuria, and provide sustained volume decongestion without triggering compensatory activation of the renin\u2013angiotensin\u2013aldosterone system. By targeting both upstream bioenergetic strain and downstream fibrotic remodeling (YAP\/TAZ axis), SGLT2 inhibitors complement standard immunosuppression to protect allograft architecture, reduce cardiovascular morbidity, and improve long-term transplant outcomes.<\/jats:p>","DOI":"10.3390\/ijms27198547","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:26:11Z","timestamp":1790256371000},"page":"8547","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Influence of SGLT2 Inhibitors on the Immune System and Inflammatory Processes in Kidney Transplantation"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-4365","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Garc\u00eda-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-7052","authenticated-orcid":false,"given":"Pablo","family":"Ort\u00edz-Lazareno","sequence":"additional","affiliation":[{"name":"Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara 44340, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8755-9058","authenticated-orcid":false,"given":"Leonardo","family":"Pazar\u00edn-Villase\u00f1or","sequence":"additional","affiliation":[{"name":"Western Biomedical Research Center, Mexican Social Security Institute, Guadalajara 44340, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-4371","authenticated-orcid":false,"given":"Elodia Nataly","family":"D\u00edaz-de la Cruz","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9451-6531","authenticated-orcid":false,"given":"Alondra","family":"Mora-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Nutrigenomics, University Center of Health Services, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-8223","authenticated-orcid":false,"given":"Jorge","family":"Andrade-Sierra","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7868-667X","authenticated-orcid":false,"given":"Ernesto Germ\u00e1n","family":"Cardona-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia Elena","family":"Totsuka-Sutto","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Francisco","family":"G\u00f3mez-Hermosillo","sequence":"additional","affiliation":[{"name":"Departamento de Cirug\u00eda General, Hospital Civil de Guadalajara \u201cJuan I Menchaca\u201d, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Casillas-Moreno","sequence":"additional","affiliation":[{"name":"Departamento de Cirug\u00eda General, Hospital Civil de Guadalajara \u201cJuan I Menchaca\u201d, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2004-7899","authenticated-orcid":false,"given":"Tannia Isabel","family":"Campos-Bayardo","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-9686","authenticated-orcid":false,"given":"Daniel","family":"Rom\u00e1n-Rojas","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0798-0078","authenticated-orcid":false,"given":"Juan Antonio","family":"Garz\u00f3n-Lamarque","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-6135","authenticated-orcid":false,"given":"Alejandra Guillermina","family":"Miranda-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1600-6143.2012.04323.x","article-title":"Quantification of the early risk of death in elderly kidney transplant recipients","volume":"13","author":"Gill","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMra2014530","article-title":"Long-term survival after kidney transplantation","volume":"385","author":"Hariharan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nri3215","article-title":"The impact of infection and tissue damage in solid-organ transplantation","volume":"12","author":"Chong","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e70233","DOI":"10.1111\/ctr.70233","article-title":"Potential role of SGLT-2 inhibitors in improving allograft function and reducing rejection in kidney transplantation","volume":"39","author":"Demir","year":"2025","journal-title":"Clin. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MOT.0000000000000180","article-title":"Changing paradigms in organ preservation and resuscitation","volume":"20","author":"Ali","year":"2015","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12146","article-title":"Inflammatory triggers of acute rejection of organ allografts","volume":"258","author":"Mori","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000347132","article-title":"Damage-associated molecular patterns control neutrophil recruitment","volume":"5","author":"Pittman","year":"2013","journal-title":"J. Innate Immun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.coi.2021.07.013","article-title":"Innate control of adaptive immunity and adaptive instruction of innate immunity: Bi-directional flow of information","volume":"73","author":"McDaniel","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104278","DOI":"10.1016\/j.cellimm.2020.104278","article-title":"Tissue-resident macrophage inflammaging aggravates homeostasis dysregulation in age-related diseases","volume":"361","author":"Yue","year":"2021","journal-title":"Cell Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ki.2014.430","article-title":"Dendritic cells and innate immunity in kidney transplantation","volume":"87","author":"Zhuang","year":"2015","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e22078","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cytogfr.2014.07.002","article-title":"Danger, diversity and priming in innate antiviral immunity","volume":"25","author":"Collins","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/all.13940","article-title":"Proteolytic, lipidergic and polysaccharide molecular recognition shape innate responses to house dust mite allergens","volume":"75","author":"Jacquet","year":"2020","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/978-981-15-0602-4_27","article-title":"Autophagy and the immune response","volume":"1206","author":"Cui","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","article-title":"Release mechanisms of major DAMPs","volume":"26","author":"Murao","year":"2021","journal-title":"Apoptosis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MNH.0000000000000190","article-title":"Ischemia as a factor affecting innate immune responses in kidney transplantation","volume":"25","author":"Kasimsetty","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e20230187","DOI":"10.1590\/2175-8239-jbn-2023-0187en","article-title":"SGLT2 inhibitors and NLRP3 inflammasome: Potential target in diabetic kidney disease","volume":"46","author":"Machado","year":"2024","journal-title":"J. Bras. Nefrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation","volume":"110","author":"Lee","year":"2026","journal-title":"Transplantation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.4049\/jimmunol.178.8.4717","article-title":"Cutting edge: Tlr5\u2212\/\u2212 mice are more susceptible to Escherichia coli urinary tract infection","volume":"178","author":"Hawn","year":"2007","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1093\/ndt\/gfq589","article-title":"Intragraft Toll-like receptor profiling in acute renal allograft rejection","volume":"25","author":"Dessing","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/CS20100190","article-title":"A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort","volume":"119","author":"Banas","year":"2010","journal-title":"Clin. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/TP.0b013e31825db680","article-title":"TLR4 mRNA levels as tools to estimate risk for early posttransplantation kidney graft dysfunction","volume":"94","author":"Campos","year":"2012","journal-title":"Transplantation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1073\/pnas.0810169106","article-title":"Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation","volume":"106","author":"Krick","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.healun.2009.09.008","article-title":"Upregulation of the apoptosis-related inflammasome in cardiac allograft rejection","volume":"29","author":"Seto","year":"2010","journal-title":"J. Heart Lung Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2008.08.016","article-title":"The innate immune response in ischemic acute kidney injury","volume":"130","author":"Jang","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2011.07.001","article-title":"Immunopathogenesis of ischemia\/reperfusion-associated tissue damage","volume":"141","author":"Ioannou","year":"2011","journal-title":"Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ndt\/gfk047","article-title":"Macrophages contribute to the initiation of ischaemic acute renal failure in rats","volume":"21","author":"Jo","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1681\/ASN.2010040430","article-title":"Dangers within: DAMP responses to damage and cell death in kidney disease","volume":"22","author":"Rosin","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2015010095","article-title":"Sphingosine 1-phosphate receptor 3-deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury","volume":"27","author":"Bajwa","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nri2132","article-title":"Tolerogenic dendritic cells and the quest for transplant tolerance","volume":"7","author":"Morelli","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.4049\/jimmunol.178.9.5899","article-title":"NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury","volume":"178","author":"Li","year":"2007","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ki.2009.259","article-title":"Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury","volume":"76","author":"Gandolfo","year":"2009","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1681\/ASN.2009020182","article-title":"B cells limit repair after ischemic acute kidney injury","volume":"21","author":"Jang","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.31729\/jnma.8190","article-title":"Mean warm ischemia time among kidney transplant patients in a tertiary care centre: A descriptive cross-sectional study","volume":"61","author":"Shrestha","year":"2023","journal-title":"JNMA J. Nepal. Med. Assoc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1681\/ASN.V34965","article-title":"Functional integrity of proximal tubule cells. Effects of hypoxia and ischemia","volume":"3","author":"You","year":"1992","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/01.tp.0000296055.76452.1b","article-title":"The relative effects of warm and cold ischemic injury in an experimental model of nonheartbeating donor kidneys","volume":"85","author":"Hosgood","year":"2008","journal-title":"Transplantation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0012.2005.00373.x","article-title":"Causes of early acute graft failure after liver transplantation: Analysis of a 17-year single-centre experience","volume":"19","author":"Varotti","year":"2005","journal-title":"Clin. Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1016\/j.transproceed.2008.10.004","article-title":"Ischemia\/reperfusion injury in kidney transplantation: Mechanisms and prevention","volume":"40","author":"Kosieradzki","year":"2008","journal-title":"Transplant. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1074-7613(01)00117-0","article-title":"Innate immune responses to transplants: A significant variable with cadaver donors","volume":"14","author":"Baldwin","year":"2001","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0008-6363(99)00187-X","article-title":"The role of neutrophils in myocardial ischemia-reperfusion injury","volume":"43","author":"Jordan","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrneph.2014.170","article-title":"Dendritic cells and macrophages in the kidney: A spectrum of good and evil","volume":"10","author":"Rogers","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ricketts, T.D., Prieto-Dominguez, N., Gowda, P.S., and Ubil, E. (2021). Mechanisms of macrophage plasticity in the tumor environment: Manipulating activation state to improve outcomes. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.642285"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102911","DOI":"10.1016\/j.autrev.2021.102911","article-title":"Monocytes and macrophages in ANCA-associated vasculitis","volume":"20","author":"Vegting","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, H., Li, Z., and Li, W. (2021). M2 macrophages serve as critical executor of innate immunity in chronic allograft rejection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.648539"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00467-017-3774-5","article-title":"A review of the role of immune cells in acute kidney injury","volume":"33","author":"Bonavia","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1152\/physiol.00046.2014","article-title":"Macrophages in kidney injury, inflammation, and fibrosis","volume":"30","author":"Cao","year":"2015","journal-title":"Physiology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-981-13-8871-2_13","article-title":"Macrophages in renal fibrosis","volume":"1165","author":"Meng","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tem.2024.02.003","article-title":"Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors","volume":"35","author":"Mashayekhi","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: Recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.4049\/jimmunol.167.10.5887","article-title":"Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes","volume":"167","author":"Kawai","year":"2001","journal-title":"J. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s11010-022-04652-5","article-title":"Toll-like receptors 2 and 4 stress signaling and sodium-glucose cotransporter-2 in kidney disease","volume":"478","author":"Shelke","year":"2023","journal-title":"Mol. Cell Biochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12016-021-08885-y","article-title":"Defects of the innate immune system and related immune deficiencies","volume":"63","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/09680519050110011101","article-title":"Evolution and integration of innate immune recognition systems: The Toll-like receptors","volume":"11","author":"Takeda","year":"2005","journal-title":"J. Endotoxin Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2014.03.006","article-title":"Effect of aging on microRNAs and regulation of pathogen recognition receptors","volume":"29","author":"Olivieri","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ndt\/gfr271","article-title":"Toll-like Receptor 3 ligands induce CD80 expression in human podocytes via an NF-\u03baB-dependent pathway","volume":"27","author":"Shimada","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e137191","DOI":"10.1172\/jci.insight.137191","article-title":"Free light chains injure proximal tubule cells through STAT1-HMGB1-TLR axis","volume":"5","author":"Upadhyay","year":"2020","journal-title":"JCI Insight"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"F1283","DOI":"10.1152\/ajprenal.00040.2018","article-title":"Intrarenal Toll-like Receptor 4 and Toll-like Receptor 2 expression correlates with injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"315","author":"Ford","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/iji.12446","article-title":"TLR-2, TLR-4 and MyD88 genes expression in renal transplant acute and chronic rejections","volume":"46","author":"Sharbafi","year":"2019","journal-title":"Int. J. Immunogenet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.trim.2018.02.005","article-title":"Expression patterns of Toll Like Receptor (TLR)-2, TLR-4 and myeloid differentiation primary response gene 88 (MYD88) in renal transplant patients developing allograft dysfunction; A cohort study","volume":"48","author":"Hosseinzadeh","year":"2018","journal-title":"Transpl. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12933-023-02027-8","article-title":"Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: Data from the DELIGHT trial","volume":"22","author":"Koshino","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4049\/jimmunol.168.3.1286","article-title":"In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-\u03b3 and TNF-\u03b1 mediated up-regulation during inflammation","volume":"168","author":"Wolfs","year":"2002","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1172\/JCI22832","article-title":"Renal-associated TLR2 mediates ischemia\/reperfusion injury in the kidney","volume":"115","author":"Leemans","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.109.880187","article-title":"Myocardial ischemia\/reperfusion injury is mediated by leukocytic Toll-like receptor-2 and reduced by systemic administration of a novel anti-Toll-like receptor-2 antibody","volume":"121","author":"Arslan","year":"2010","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1172\/JCI31008","article-title":"TLR4 activation mediates kidney ischemia\/reperfusion injury","volume":"117","author":"Wu","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.4049\/jimmunol.178.10.6252","article-title":"TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways","volume":"178","author":"Shigeoka","year":"2007","journal-title":"J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00467-009-1422-4","article-title":"Toll-like receptors 2 and 4 in renal ischemia\/reperfusion injury","volume":"25","author":"Rusai","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1242\/dmm.003533","article-title":"Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling","volume":"3","author":"Wang","year":"2010","journal-title":"Dis. Model Mech."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Vall\u00e9s, P.G., Gil Lorenzo, A.F., Garcia, R.D., Cacciamani, V., Benardon, M.E., and Costantino, V.V. (2023). Toll-like receptor 4 in acute kidney injury. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021415"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJM200008033430506","article-title":"Innate immunity","volume":"343","author":"Medzhitov","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40620-021-01153-4","article-title":"The innate immune system in human kidney inflammaging","volume":"35","author":"Sepe","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_74","first-page":"1671","article-title":"Ischemia-reperfusion injury in kidney transplantation: A review of cellular mechanisms and therapeutic opportunities","volume":"7","author":"Huang","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6795845","DOI":"10.1155\/2019\/6795845","article-title":"Role of Toll-Like Receptors in Actuating Stem\/Progenitor Cell Repair Mechanisms: Different Functions in Different Cells","volume":"2019","author":"Sallustio","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_76","first-page":"549","article-title":"Complement and innate immunity in kidney transplantation","volume":"38","author":"Conti","year":"2018","journal-title":"Semin. Nephrol."},{"key":"ref_77","first-page":"123","article-title":"Complement components in renal ischemia-reperfusion injury","volume":"19","author":"Farrar","year":"2014","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1590\/S1679-45082015RW3161","article-title":"Ischemia and reperfusion injury in renal transplantation: Hemodynamic and immunological paradigms","volume":"13","author":"Matos","year":"2015","journal-title":"Einstein"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2018.01.025","article-title":"Ischemia-reperfusion injury reduces long-term renal allograft survival: Mechanisms and therapeutics","volume":"28","author":"Zhao","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.25497","article-title":"Hypoxia and hypoxia-inducible factors in liver biology and disease","volume":"55","author":"Nath","year":"2012","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nm.2507","article-title":"Ischemia and reperfusion\u2014From mechanism to translation","volume":"17","author":"Eltzschig","year":"2011","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury","volume":"121","author":"Bonventre","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"14201","DOI":"10.1016\/S0021-9258(18)67004-8","article-title":"Mechanism of calcium-induced mitochondrial dysfunction. Implications for the pathophysiology of acute renal failure","volume":"261","author":"Malis","year":"1986","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-pharmtox-010715-103335","article-title":"Mitochondrial Dysfunction and Myocardial Ischemia-Reperfusion: Implications for Novel Therapies","volume":"57","author":"Lesnefsky","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1681\/ASN.2014030262","article-title":"Regulated cell death in AKI","volume":"25","author":"Linkermann","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_87","first-page":"525","article-title":"Human Intestinal Ischemia-Reperfusion\u2013Induced Inflammation Characterized","volume":"16","author":"Grootjans","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1432-2277.2010.01158.x","article-title":"Role of heme oxygenase-1 in transplantation","volume":"23","author":"Pratschke","year":"2010","journal-title":"Transpl. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrneph.2016.41","article-title":"Role of TLRs and DAMPs in allograft inflammation and transplant outcomes","volume":"12","author":"Braza","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Ludes, P.-O., de Roquetaillade, C., Chousterman, B.G., Pottecher, J., and Mebazaa, A. (2021). Role of Damage-Associated Molecular Patterns in Septic Acute Kidney Injury, From Injury to Recovery. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.606622"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: Sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01146.x","article-title":"PAMPs and DAMPs: Signal 0s that spur immunity and autoimmunity","volume":"249","author":"Tang","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2007.02.006","article-title":"Damage-associated molecular pattern molecules","volume":"124","author":"Lotze","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"ref_95","first-page":"1108","article-title":"Beyond tissue injury-damage-associated molecular patterns, Toll-like receptors, and inflammasomes in chronic kidney disease","volume":"86","author":"Anders","year":"2014","journal-title":"Kidney Int."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_99","first-page":"100792","article-title":"SGLT2 inhibitors in kidney transplant recipients: Clinical updates and mechanistic insights","volume":"37","author":"Lee","year":"2023","journal-title":"Transplant. Rev."},{"key":"ref_100","first-page":"745","article-title":"SGLT2 inhibitors and kidney protection: Mechanisms and clinical evidence","volume":"14","author":"Nespoux","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Henkel, L., Ingmanns, L., Westphal, F., Menke, A.F., Pavenst\u00e4dt, H., Jehn, U., Boeckel, G.R., and Reuter, S. (2026). SGLT2 inhibitors in kidney transplant recipients: Metabolic changes, potassium-related safety and implications for albuminuria assessment. Front. Transplant., 5.","DOI":"10.3389\/frtra.2026.1927374"},{"key":"ref_106","first-page":"112","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: A combined human-rodent pilot study","volume":"19","author":"Rajasekeran","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s11658-023-00457-6","article-title":"Empagliflozin improves renal ischemia-reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK-OPA1 pathway promotion","volume":"28","author":"Yang","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., Sango, K., and Utsunomiya, K. (2017). SGLT2 inhibitors as a novel therapeutic strategy for diabetic kidney disease. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051083"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.clinthera.2023.10.014","article-title":"SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review","volume":"46","author":"Maxson","year":"2024","journal-title":"Clin. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e72142","DOI":"10.1096\/fj.202601959R","article-title":"SGLT2 Inhibition Attenuates Renal Tubular Senescence by Suppressing CTRP1 -Mediated Glucotoxic Stress in Diabetic Kidney Disease","volume":"40","author":"Gu","year":"2026","journal-title":"FASEB J."},{"key":"ref_112","first-page":"885","article-title":"Intrarenal renin-angiotensin system and SGLT2 inhibitors","volume":"41","author":"Nishiyama","year":"2018","journal-title":"Hypertens. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8540354","DOI":"10.1155\/jdr\/8540354","article-title":"Sodium-glucose otransporter 2 inhibitors in diabetic solid organ transplant recipients: A systematic review and meta-analysis of comparative studies","volume":"2026","author":"Geum","year":"2026","journal-title":"J. Diabetes Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13578-026-01606-y","article-title":"Dapagliflozin attenuates hypoxia\/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK","volume":"16","author":"Tsai","year":"2026","journal-title":"Cell Biosci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2017","journal-title":"Diabetologia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Chung, M.C., Chang, Y.T., Guo, Y.J., Chung, C.J., Wu, L.Y., Wu, M.J., and Shieh, J.-J. (2026). SGLT2 inhibitors mitigate contrast-induced acute kidney injury in diabetes: Clinical and experimental evidence. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27041684"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","author":"Bessho","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/MNH.0000000000000749","article-title":"Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients","volume":"30","author":"Jenssen","year":"2021","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"sfae370","DOI":"10.1093\/ckj\/sfae370","article-title":"Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: Physiology and clinical implications","volume":"18","author":"Sridhar","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/nep.13941","article-title":"Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence","volume":"26","author":"Kanbay","year":"2021","journal-title":"Nephrology"},{"key":"ref_123","first-page":"CD009966","article-title":"Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients","volume":"8","author":"Lo","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1007\/s11255-026-05162-9","article-title":"Blood pressure effects of SGLT2 inhibitors in kidney transplant recipients: A systematic review and meta-analysis","volume":"58","author":"Ahmad","year":"2026","journal-title":"Int. Urol. Nephrol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Long, J., Zhao, J., Gu, X., and Huang, C. (2026). Post-transplant diabetes mellitus after kidney transplantation: Pathogenesis, risk factors, and management strategies. Front. Endocrinol., 17.","DOI":"10.3389\/fendo.2026.1829579"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplant diabetes mellitus","volume":"14","author":"Sharif","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/gfs583","article-title":"Novel views on new-onset diabetes after transplantation: Development, prevention and treatment","volume":"28","author":"Hecking","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.transproceed.2026.04.006","article-title":"Urinary tract infections in kidney transplant recipients: A narrative review","volume":"58","author":"Apicellaa","year":"2026","journal-title":"Transplant. Proc."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/dom.15575","article-title":"An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management","volume":"26","author":"Kanbay","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1600-6143.2011.03855.x","article-title":"New-onset diabetes after kidney transplantation-changes and challenges","volume":"12","author":"Yates","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2215\/CJN.0000000951","article-title":"Efficacy, mechanisms, and safety of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients: A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Sridhar","year":"2026","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kahvecioglu, S., Celik, H., Karatutlu, A.S., Boz, S.E.G., Ozdemir, P., Akarsu, O., Sensoy, N.N.O., and Aktas, N. (2026). Effects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Data. J. Clin. Med., 15.","DOI":"10.3390\/jcm15135303"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00592-021-01681-2","article-title":"Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy","volume":"58","author":"Castoldi","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Pham, P.T., and Pham, P.T. (2022). Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients. Front. Nephrol., 2.","DOI":"10.3389\/fneph.2022.1014241"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/15269248231189880","article-title":"Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients","volume":"33","author":"Sweiss","year":"2023","journal-title":"Prog. Transplant."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J.J., G\u00f3rriz, J.L., Cebri\u00e1n-Cuenca, A., Castro Conde, A., and Velasco Arribas, M. (2024). Clinical recommendations for managing genitourinary adverse effects in patients treated with SGLT-2 inhibitors: A multidisciplinary expert consensus. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216509"},{"key":"ref_140","first-page":"e96393","article-title":"Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: A Case Series and Clinical Reflections","volume":"17","author":"Sultan","year":"2025","journal-title":"Cureus"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis","volume":"11","author":"Dutta","year":"2022","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"112978","DOI":"10.1016\/j.diabres.2025.112978","article-title":"Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes","volume":"230","author":"Kim","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination therapy: An upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger, E., Mihaljevi\u0107, V., Steiner, K., \u0160ari\u0107, S., Kurevija, T., Majnari\u0107, L.T., \u0106ur\u010di\u0107, I.B., and Canecki-Var\u017ei\u0107, S. (2023). Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20176671"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"20386","DOI":"10.1038\/s41598-024-71416-0","article-title":"SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis","volume":"14","author":"Hirashima","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: An update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor\u2013dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/ehf2.15345","article-title":"Interconnected pathways and emerging therapies in chronic kidney disease and heart failure: A comprehensive review","volume":"12","author":"Bauersachs","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4229194","DOI":"10.1155\/2021\/4229194","article-title":"Exploring the pleiotropic genes and therapeutic targets associated with heart failure and chronic kidney disease by integrating metaCCA and SGLT2 inhibitors\u2019 target prediction","volume":"2021","author":"Li","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"109089","DOI":"10.1016\/j.pharmthera.2026.109089","article-title":"Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring","volume":"286","author":"Li","year":"2026","journal-title":"Pharmacol. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ejh.70197","article-title":"Anemia of chronic disease revisited: Hepcidin dysregulation, erythropoietic failure, and emerging roles of SGLT2 inhibition","volume":"117","author":"Abdulgayoom","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e188933","DOI":"10.1172\/JCI188933","article-title":"SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress","volume":"135","author":"Maekawa","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Hou, Y.C., Zheng, C.M., Yen, T.H., and Lu, K.C. (2020). Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217833"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: From biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: From glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMc1611290","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Parving","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 Inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: A meta-analysis","volume":"335","author":"Neuen","year":"2026","journal-title":"JAMA"},{"key":"ref_168","unstructured":"Nuffield Department of Population Health Renal Studies Group, and SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamacardio.2021.0660","article-title":"Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial","volume":"6","author":"Zelniker","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_171","first-page":"446","article-title":"Effects of dapagliflozin in patients with kidney disease, with and without heart failure","volume":"10","author":"McMurray","year":"2022","journal-title":"JACC Heart Fail."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/ndt\/gfae106","article-title":"The long-term effects of dapagliflozin in chronic kidney disease: A time-to-event analysis","volume":"39","author":"McEwan","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8547\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:12:23Z","timestamp":1790673143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":173,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198547"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198547","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}